aTyr Pharma advances ATYR0101 to IND candidate stage for pulmonary fibrosis

aTyr Pharma (ATYR) announced that it has advanced its next investigational new drug, IND, candidate, ATYR0101, which has been selected to be showcased in an oral presentation at the American Thoracic Society, ATS, 2025 Respiratory Innovation Summit, which is scheduled to take place May 16 – 17, 2025, in San Francisco, CA. The presentation will feature preclinical data generated to date for ATYR0101, a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase, DARS, that binds to latent transforming growth factor beta binding protein 1 to induce cell death of myofibroblasts, which are key cells responsible for driving the progression of fibrosis.